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Abstract: The nucleotide-binding domain and leucine-rich repeat related (NLR) family, pyrin domain
containing 3 (NLRP3) inflammasome is a multimeric protein complex that recognizes various danger
or stress signals from pathogens, the host, and the environment, leading to activation of caspase-1
and inducing inflammatory responses. This pro-inflammatory protein complex plays critical roles in
pathogenesis of a wide range of diseases including neurodegenerative diseases, autoinflammatory
diseases, and metabolic disorders. Therefore, intensive efforts have been devoted to understanding
its activation mechanisms and to searching for its specific inhibitors. Approximately forty natural
compounds with anti-NLRP3 inflammasome properties have been identified. Here, we provide an
update about new natural compounds that have been identified within the last three years to inhibit
the NLRP3 inflammasome and offer an overview of the underlying molecular mechanisms of their
anti-NLRP3 inflammasome activities.
Keywords: NLRP3 inflammasome; natural compounds; inflammatory diseases; medicinal herbs
1. Introduction
The nucleotide-binding domain and leucine-rich repeat related (NLR) family, pyrin
domain containing 3 (NLRP3) inflammasome is a cytosolic protein complex in the innate im-
mune cells. It is composed of NLRP3, apoptotic speck protein containing a caspase recruit-
ment domain (ASC), and caspase-1 [1,2]. In response to a variety of pathogen-associated
molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs), the sen-
sor NLRP3 recruits the adaptor ASC, which further recruits the effector caspase-1 to form
the inflammasome complex. Caspase-1 autocleaves itself to generate the active enzyme,
which cleaves pro-interleukin (IL)-1β and pro-IL-18 to generate the mature cytokines IL-1β
and IL-18. Active caspase-1 also cleaves gasdermin D to induce pyroptotic cell death to
amplify the inflammatory responses [3,4].
The NLRP3 inflammasome has become an attractive therapeutic target because grow-
ing evidence has shown that its inappropriate activation is involved in the pathogenesis of
many complex diseases, such as Alzheimer’s disease, type 2 diabetes, and gout [5,6]. In
clinical practice, protein-based therapies that block the action of IL-1β have been tested in
patients. For example, injection of anakinra, a recombinant human IL-1 receptor antagonist
protein, in diabetic patients suppressed systemic inflammation, lowered plasma glucose,
and improved β-cell secretory function [7,8]. Rilonacept, a soluble decoy IL-1 receptor,
reduced inflammatory markers, pain, and swelling in gout patients in clinical trials [9].
While these protein-based therapies are promising, they are costly, require frequent injec-
tion, and block only one downstream pathway of the NLRP3 inflammasome. Therefore,
it is highly desirable to identify other potential therapeutic interventions that target the
NLRP3 inflammasome.
Remarkably, many natural compounds or nutrient molecules have been shown to
suppress activation of the NLRP3 inflammasome. Two recent reviews [10,11] provide a
comprehensive overview of these natural products. In this review, we will (1) introduce the
background information about NLRP3 inflammasome activation and its involvement in
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diseases, and (2) provide an update of natural compounds with anti-NLRP3 inflammasome
functions that have been identified within the last three years.
2. NLRP3 Inflammasome and Its Involvement in Diseases
2.1. Activation of the NLRP3 Inflammasome
The molecular mechanisms of NLRP3 inflammasome activation have been reviewed in
depth [12–16]. Here, we summarize general principles of NLRP3 inflammasome activation
(Figure 1) to provide background knowledge about how natural compounds target this
key pro-inflammatory protein complex.
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Figure 1. Molecular mechanisms of NLRP3 inflammasome activation. The NLRP3 inflammasome is activated through
an initial priming step followed by an activating step. The priming signals, such as lipopolysaccharide (LPS), activate
NF-κB signaling, which induces transcription of the Nlrp3 and Il1b genes. The activating signals, such as ATP, nigericin, free
fatty acids (FFAs), monosodium urate (MSU) or cholesterol crystals, can trigger a series of cellular events, which typically
include potassium efflux, calcium mobilization, mitochondrial (mt) damage (leading to release of reactive oxygen species
(ROS), DNA, and cardiolipin), trans-Golgi disassembly, and lysosomal rupture. These upstream cellular events converge
on the NLRP3 protein, causing its conformational change and leading to oligomerization of NLRP3 with the assistance of
NEK7 protein. Oligomerized NLRP3 recruits ASC, which further recruits caspase-1, to for the NLRP3 inflammasome
complex. Caspase-1 auto leaves itself to generate the active enzyme, which cleaves pro-IL-1β and pro-IL- 8 to release
mature cytokines. Active caspase-1 also cleaves gasder in D to induce pyroptosis. Both cytokine releas and pyropototic
cell death trigger inflammation.
Although the precise molecular mechanisms of NLRP3 inflammasome activation are
not fully understood, it is generally accepted that NLRP3 inflammasome activation requires
an initial priming step followed by an activation step (Figure 1) [12,13]. A priming signal,
such as lipopolysaccharide (LPS), activates nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB) signaling, leading to increased expression of the Il1b and Nlrp3
genes. The priming signal also induces the deubiquitination of NLRP3 protein, which is a
prerequisite for optimal activation of the NLRP3 inflammasome [17–19]. Activating signals
for the NLRP3 inflammasome include a variety of molecules with diverse and un-related
chemical structures. For example, ATP, nigericin, alum, free fatty acids (FFAs), cholesterol
crystals, or monosodium urate (MSU) crystals can serve as an activating signal to promote
the assembly and formation of the NLRP3 inflammasome [12,13].
The exact signaling cascade from activating signals or NLRP3 agonists to inflamma-
some assembly is still not clear. Some upstream cellular events that have been implicated
in NLRP3 inflammasome formation include potassium efflux, calcium mobilization, pro-
duction of mitochondrial reactive oxygen species (ROS), release of mitochondrial DNA,
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cytosolic exposure of mitochondrial inner member lipid cardiolipin, cellular transloca-
tion of inflammasome subunits, lysosomal destabilization, and trans-Golgi disassembly
(Figure 1) [2,12,14]. However, some of these upstream cellular events are agonist specific.
For example, lysosomal destabilization is often observed when crystal agonists or protein
aggregates are used to activate the NLRP3 inflammasome [20–22]. In general, it seems that
all NLRP3 agonists trigger cellular stress, which could be sensed by the NLRP3 protein,
leading to NLRP3 inflammasome assembly and activation.
The NLRP3 protein contains an N-terminal pyrin domain (PYD), a central nucleotide-
binding and oligomerization domain (NACHT), and a C-terminal leucine-rich repeat
domain (LRR) (Figure 1) [6]. In the absence of activating signals, LRR internally interacts
with NACHT, which causes the NLRP3 protein to form a closed structure. The activating
signal triggers a conformational transition of NLRP3 proteins, leading to the oligomeriza-
tion of NLRP3 through their NACHT domains. Recently, it has been shown that adjacent
NLRP3 proteins are bridged through never in mitosis gene a (NIMA)-related kinase 7
(NEK7) to facilitate oligomerization [23]. Oligomerized NLRP3 forms a platform to recruit
ASC through PYD–PYD interaction. ASC contains an N-terminal PYD and a C-terminal
caspase activation and recruitment domain (CARD). After PYD of ASC interacts with PYD
of NLRP3, the CARD of ASC further recruits caspase-1 through CARD–CARD interaction,
since caspase-1 contains an N-terminal CARD and a C-terminal caspase domain. The
recruitment of caspase-1 in the inflammasome complex triggers its autocleavage to gener-
ate the active enzyme [1,2]. Because both PYD and CARD form filaments, the resulting
NLRP3 inflammasome is a highly polymerized and filamentous protein complex with high
molecular mass [24].
2.2. Involvement of the NLRP3 Inflammasome in Diseases
While proper innate immune responses protect against insults, aberrant activation
of the NLRP3 inflammasome causes or contributes to the onset and progress of various
diseases. Here, we summarize the involvement of the NLRP3 inflammasome in a wide
range of diseases to highlight the pathophysiological roles of this protein complex.
Cryopyrin-associated periodic syndromes (CAPS). Dominant missense mutations in
the NLRP3 gene in humans result in a hyperactive NLRP3 inflammasome and overproduc-
tion of inflammatory cytokines, leading to CAPS, a group of autoinflammatory diseases
that include familial cold autoinflammatory syndrome (FCAS), Muckle–Wells syndrome
(MWS), and neonatal onset multisystem inflammatory disease (NOMID) [25,26]. CAPS
patients experience varying degrees of systemic inflammation. FCAS, at the mild end,
is characterized by cold-induced inflammatory episodes including recurrent hives, joint
pain, and fever. MWS, of intermediate severity, manifests recurrent inflammatory attacks
often accompanied by progressive hearing loss and sometimes amyloidosis in the kidney.
The most severe NOMID manifests persistent inflammation from birth, as well as severe
tissue damage mainly affecting the nervous system, skin, and joints. Mice carrying specific
CAPS-associated mutations in the Nlrp3 gene demonstrate inflammatory symptoms similar
to those seen in CAPS patients [27,28].
Gout. NLRP3 inflammasome activation is implicated in the etiology of gout. Gout
is a common form of inflammatory arthritis characterized by severe and intense pain,
swelling, redness, and heat often occurring at the big toe joint [29]. Gouty arthritis is
caused by the deposition of MSU crystals in joints, which—remarkably—activate the
NLRP3 inflammasome [30]. Deletion of the Nlrp3, Pycard (Asc), or Casp1 gene in mice leads
to reduced articular inflammation in response to MSU injection in joints [31].
Multiple sclerosis (MS). MS is an autoimmune inflammatory disease of the brain and
spinal cord. In MS, inflammation occurs in the myelin layer around the nerves and causes
scars or lesions in the myelin, disrupting communication in the nervous system [32]. The
most common symptoms of MS are fatigue and difficulty walking, but the symptoms,
severity, and duration can vary widely among patients. Expression of the CASP1 and IL18
genes increased in the peripheral blood mononuclear cells (PBMCs) of MS patients [33].
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Expression of the Nlrp3 gene increased in the spinal cord during the progression of experi-
mental autoimmune encephalomyelitis (EAE), an animal model of MS, and deletion of the
Nlrp3, Casp1, Pycard, or Il1b genes in mice led to resistance to EAE [34–36].
Alzheimer’s disease (AD). AD is a progressive brain disorder caused by gradual
death of neuronal cells in the hippocampus and cerebral neocortex [37]. The symptoms
of AD include memory loss, problems with communication, reasoning, and thinking, and
eventually loss of ability to function independently. Expression of the NLRP3 and CASP1
genes was enhanced in the brain of AD patients [38,39]. β-amyloid deposition in the brain is
a key factor that drives the development of AD [40], and remarkably, β-amyloid aggregates
activate the NLRP3 inflammasome [22]. Knockout of the Nlrp3 or Casp1 genes reduced
neuronal inflammation and improved cognitive function in the AD mouse model [38].
Parkinson’s disease (PD). PD is a neurodegenerative disease caused by gradual death
of dopamine-producing neurons [41]. Very often, PD patients experience tremor, stiffness,
and difficulty with walking, balance, and coordination. In mice, PD can be induced by
administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a chemical leading
to the loss of dopamine-producing neurons. Nlrp3−/− mice were resistant to development
of PD after MPTP treatment [42], suggesting the involvement of the NLRP3 inflammasome
in PD etiology. In addition, aggregated α-synuclein, which is considered a key element in
the pathogenesis of PD, has been shown to activate the NLRP3 inflammasome [43].
Obesity. Obesity is a chronic progressive disease that leads to development of type
2 diabetes, heart disease, and stroke, all of which are among the top 10 leading causes of
death in the United States [44,45]. In obesity, the level of circulating LPS, which acts as the
priming signal for the NLRP3 inflammasome [5,14,15], from gut microbiota is significantly
enhanced [46,47]. Nutrient excess in obesity leads to an accumulation of metabolic stress
molecules, such as FFAs, cholesterol crystals, glucose, or amyloid polypeptides [5,14,15],
which serve as the second activation signal to promote the assembly and activation of the
NLRP3 inflammasome. Expression of the NLRP3, ASC, and IL1B genes has been shown
to increase in PBMCs, subcutaneous adipose tissue, and visceral adipose tissue in obese
humans compared to lean subjects [48,49]. When the adipose tissue or monocyte-derived
macrophages were cultured ex vivo, the levels of secreted cytokines IL-1β and IL-18 were
much higher in obese samples compared to lean samples. Cytokine levels were tightly
associated with an increased number of adipose tissue macrophages, increased plasma glu-
cose and insulin levels, and higher metabolic syndrome scores in obese patients [48,50,51].
Genetic deletion of the Nlrp3, Pycard, or Casp1 genes in diet-induced obese mice improved
glucose tolerance and insulin sensitivity, accompanied by decreased inflammatory cy-
tokines in the serum and reduced expression of inflammatory genes in metabolic tissues,
including adipose tissue and liver [52–54].
Atherosclerosis. Atherosclerosis refers to the buildup of plaque, composed of choles-
terol crystals, immune cells, and other substances, on the arterial wall [55]. Over time, the
plaque hardens and narrows the arteries and eventually leads to severe conditions such as
heart attack or stroke. In aortas of patients with coronary atherosclerosis, the levels of the
NLRP3 protein were much higher compared to individuals without atherosclerosis [56].
Cholesterol crystals activate the NLRP3 inflammasome [21]. The low-density lipoprotein
receptor deficiency (Ldlr−/−) mouse is a widely used atherosclerosis model [57]. When
these mice were transplanted with bone marrow from Nlrp3−/−, Pycard−/−, Il1b−/− or
Casp1−/− mice, they had decreased sizes of aortic lesions [21,58]. Atherosclerosis was
ameliorated upon deletion of the Casp1 gene in apolipoprotein E deficiency (ApoE−/−) mice
(also a widely used atherosclerosis mouse model) [59]. However, another study showed
that atherosclerosis in ApoE−/− mice is not dependent on the NLRP3 inflammasome [60].
The exact reasons for this discrepancy are not clear.
Type 2 diabetes. The key symptom of type 2 diabetes is an elevated glucose level
in the circulatory system, which is accompanied by insulin resistance, pancreas failure,
and chronic inflammation [61]. If not managed, type 2 diabetes leads to development
of heart disease, stroke, nerve damage, kidney disease, eye disease, and other health
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complications. The expression levels of NLRP3 inflammasome components are correlated
with the disease severity of type 2 diabetes [54]. IL-1β, one downstream product of NLRP3
inflammasome activation, activates the c-Jun N-terminal kinases (JNK) pathway, which
promotes insulin resistance by regulating phosphorylation of insulin receptor and insulin
receptor substrate-1 [53,62]. IL-1β triggers endoplasmic reticulum stress, which is involved
in the pathogenesis of type 2 diabetes [63,64]. IL-1β generated in pancreatic macrophages
is a key driver of β-cell death and therefore contributes to pancreatic failure [65].
3. Recently Identified Natural Compounds with Anti-NLRP3 Inflammasome Functions
Because of the critical involvement of the NLRP3 inflammasome in a broad range of
complex diseases, it has become an attractive therapeutic target. Protein-based therapies
that block the action of IL-1β, one of its downstream products, have shown promising
outcomes in patients with gout, CAPS, and type 2 diabetes in clinical trials [9,66,67],
suggesting that inhibition of the NLRP3 inflammasome is likely the right path to curb
NLRP3 inflammasome-mediated diseases. However, these protein-based therapies have
some inherent limitations. First, their high cost limits their wide application. Second,
because these therapeutics are protein-based, they need to be administered by injections,
but some patients experience adverse effects such as redness, bruising, swelling or pain at
the injection site. Finally, some elegant genetic studies have shown that other downstream
products of the NLRP3 inflammasome, such as IL-18 or gasdermin D, contribute to disease
progress in animal models [3,27]. Therefore, inhibiting the NLRP3 inflammasome activation
instead of targeting its downstream products may offer greater therapeutic promise.
Small chemical molecules are cost-effective and less invasive compared to protein-
based therapies. Some synthetic small chemical molecules, such as Bay11-7082 [68], CY-
09 [69], and MCC950 [70], have been shown to effectively and directly impede NLRP3
inflammasome assembly and activation. To date, MCC950 is the most potent and spe-
cific inhibitor of the NLRP3 inflammasome. Unfortunately, its phase II clinical trial for
rheumatoid arthritis was suspended because of hepatic toxicity [71]. For many of these
inhibitors, the underlying mechanisms of their inhibitory actions are not clear and need
further investigation. Moreover, future studies are warranted to explore their specificity,
potency, and long-term safety in humans.
Natural compounds have been a major source of traditional medicines and the source
of new drug discovery in history [72,73]. Many blockbuster drugs on the market, such as
artemisinin, metformin, and ephedrine, are derived directly or indirectly from plants [72].
In the 20th century, many pharmaceutical companies have shifted focus from isolation and
optimization of medicinal compounds from plants or other natural sources to synthesis
of chemical libraries because of low reproducibility of crude natural extracts and lack
of efficient and rapid strategies to separate and identify the active natural compounds.
However, the low success of small-chemical libraries has rekindled the interest of phar-
maceutical companies and academic researchers in natural compounds in recent years.
Nevertheless, the exceptional structural diversity and highly selective activity of natural
products has made, and will continue to make, them versatile and superior sources of drug
discovery [72]. The study of natural compounds with anti-NLRP3 inflammasome function
is still in its infancy. To date, approximately 40 natural products that inhibit activation of
the NLRP3 inflammasome have been identified. An extensive overview of these natural
compounds has been provided in two recent reviews published in 2016 and 2017 [10,11].
Here, we provide an update on new natural compounds that have been identified from
2017 to 2020 as inhibitors of the NLRP3 inflammasome.
3.1. Oridonin
Oridonin is an ent-kaurane diterpenoid (Figure 2 and Table 1) extracted from
Rabdosia rubescens, a traditional medicinal herb that has been commonly used to treat
inflammatory diseases in China for centuries [74]. Oridonin strongly suppressed NLRP3
inflammasome activation in primary macrophages by blocking formation of the inflam-
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masome complex [75]. This natural compound had no effects on the protein levels of
NLRP3, ASC, caspase-1, NEK7, or pro-IL-1β. It also had no impact on potassium efflux
or mitochondrial ROS production, when the NLRP3 inflammasome was activated using
LPS and nigericin. The inhibitory effects of oridonin on the NLRP3 inflammasome were
specific, considering it had no impact on activation of other inflammasomes, including the
Absent in melanoma 2 (AIM2) inflammasome and NLR family CARD domain-containing
protein 4 (NLRC4) inflammasome. Further investigation revealed that oridonin directly
formed a covalent bond with cysteine 279 on the NACHT domain of the NLRP3 protein
through a carbon–carbon double-bond. Binding of oridonin to the NLRP3 protein impeded
the interaction between NEK7 and NLRP3 and therefore blocked further assembly and
formation of the NLRP3 inflammasome complex. In MSU crystal-induced peritonitis and
gouty arthritis in mice, oridonin attenuated the NLRP3 inflammasome-dependent acute
inflammatory responses. After the mice were fed with a high-fat diet (HFD) for 12 weeks
to induce obesity and chronic inflammation, daily intraperitoneal administration of ori-
donin prevented further body weight gain and improved glucose tolerance and insulin
sensitivity [75].
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In a recent study [76], oridonin was reported to suppress NLRP3 inflammasome
activation in the murine macrophage-like RAW 264.7 cell line. In an LPS-induced acute
lung injury mouse model, intraperitoneal administration of oridonin reduced the protein
levels of NLRP3, caspase-1, ASC, and IL-1β in lu g tissues. Histologically, i flammatory
cell infiltration and alveolar hemorrhage of lung were blunted by oridonin treatment.
Yan et al. [77] reported that the NLRP3 inflammasome was activated in the pericontusional
cerebral cortex upon induction of traumatic brain injury in mice using the weight-drop
method. Oridonin reduced both mRNA and protein levels of the Nlrp3, Pycard, and Casp1
genes. The levels of IL-1β and IL-18, downstream products of NLRP3 inflammasome
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activation, were also decreased in the cerebral cortex. Meanwhile, oridonin treatment
attenuated the neurological deficits associated with traumatic brain injury.
These mechanistic and pathological studies suggest a high therapeutic potential of ori-
donin in NLRP3 inflammasome-mediated diseases. Hundreds of oridonin derivatives have
been designed and synthesized to improve the potency and bioavailability of oridonin in
cancer treatment [74,78]. However, none of these derivatives have been tested for their anti-
NLRP3 inflammasome functions. After oral administration of oridonin in Sprague–Dawley
rats, 18 oridonin-derived metabolites were detected in bile or urine or both, 17 in bile and
10 in urine [79]. Oridonin mainly underwent reduction, oxidation, dehydroxylation, and
glucuronic acid conjugation in vivo. It would be interesting to investigate whether these
metabolites demonstrate anti-NLRP3 inflammasome activities.
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3.2. Isoliquiritigenin
Isoliquiritigenin (ILG, 2′,4′,4-trihydroxychalcone), a flavonoid with a chalcone struc-
ture (Figure 2 and Table 1), is the main active compound of roots and rhizomes of Chinese
licorice (Glycyrrhiza uralensis), which has been used as a natural sweeter and medicinal
food worldwide [93]. ILG exhibits various bioactivities, such as antioxidant and anti-
inflammatory functions [94]. In 2014, ILG was reported, for the first time, to be a potent
inhibitor of the NLRP3 inflammasome [80]. The inhibitory effect of ILG on the NLRP3
inflammasome was considered specific since ILG had no inhibitory effects on the AIM2
inflammasome. It had no impact on mitochondrial ROS production but inhibited ASC
oligomerization during NLRP3 inflammasome activation. However, the exact molecular
targets of ILG were not further investigated. In the same study, ILG supplement (0.5% w/w)
in the HFD reduced body weight gain (despite similar food intake), improved glucose
tolerance and insulin sensitivity, inhibited hepatic steatosis, and suppressed inflammation
in epididymal white adipose tissue (eWAT). Expression of the Nlrp3, Casp1, Pycard, and Il1b
genes was also reduced in the eWAT of ILG-treated mice. Correspondingly, the release of
IL-1β and caspase-1 was diminished from ex vivo cultured eWAT of ILG-treated mice [80].
A subsequent study from Lee et al. [81] showed a HFD supplemented with 0.02% (w/w)
ILG did not affect body weight gain but slightly decreased food intake. The discrepancy
between these two studies could be attributed to differences in HFD composition and ILG
dose. Nevertheless, Lee et al. still found that supplementation of ILG inhibited hepatic
steatosis, improved glucose tolerance and insulin sensitivity, and suppressed systemic
chronic inflammation [81].
In a rat disease model of intracerebral hemorrhage (ICH), intraperitoneal administra-
tion of ILG decreased brain injury and neurological deficits, accompanied by decreased
mRNA and protein levels of the Nlrp3, Pycard, and Casp1 genes in the ipsilateral hemi-
sphere, as well as reduced levels of mature IL-1β and IL-18 in the brain and blood [82]. In
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this study, ILG was found to simultaneously dampen NF-κB signaling and boost transcrip-
tion of the Nrf2 gene in the damaged brain. NF-κB signaling is involved in the priming step
of NLRP3 inflammasome activation [12]. The Nrf2 gene expresses the transcription factor
erythroid-2 related factor 2 (Nrf2), which is a key mediator that controls the expression
of many antioxidant and detoxification enzymes and has been implicated in alleviating
NLRP3 inflammasome activity [95]. Therefore, the actions of ILG on the priming step and
Nrf2 regulation may contribute to its anti-inflammasome function in vivo.
In an LPS-induced acute lung injury mouse model, ILG alleviated the severity of
lung injury, reduced the production of IL-1β, and lowered protein levels of NLRP3, ASC,
cleaved caspase-1, and pro-IL-1β [83]. In carrageenan-induced pleurisy and lung injury in
mice, pre-treatment with ILG reduced lung injury, decreased the levels of cytokines and
neutrophil infiltration in the pleural exudate, as well as protein levels of NLRP3, cleaved
caspase-1, and mature IL-1β in the lung tissues [84].
ILG has been shown to block NLRP3 inflammasome assembly and therefore suppress
activation of the NLRP3 inflammasome in macrophages. ILG also has demonstrated potent
anti-inflammatory function in multiple disease models associated with chronic or acute
inflammation. Therefore, ILG is a new promising inhibitor of the NLRP3 inflammasome.
However, further investigation is warranted to reveal the exact molecular mechanisms of
the anti-NLRP3 inflammasome action of ILG.
Four ILG derivatives, including 4,4′-Diacetoxy-2′-hydroxy chalcone, 2′,4′-Dimethoxy-
4-hydroxychalcone, 4-Acetoxy-2′,4′-dimethoxychalcone and 2′,4′-Dimethoxychalcone, ex-
hibited potent blood glucose-lowering activities in Swiss albino mice [96]. Another ILG
derivative was shown to inhibit cancer cell proliferation [97], and a sixth was found to
be neuroprotective [98]. Using human liver microsomes, seven phase I metabolites of
ILG—liquiritigenin, 2′,4,4′,5′-tetrahydroxychalcone, sulfuretin, butein, davidigenin, cis-
6,4′-dihydroxyaurone, and trans-6,4′-dihydroxyaurone—were identified [99]. In lung can-
cer cells, ILG was found to be converted into 2, 4, 2′, 4′-Tetrahydroxychalcone (THC) [100].
Interestingly, ILG inhibited activity of kinase Src in these cancer cells but not in the cell-
free system, whereas THC inhibited Src activity in both the cancer cells and the cell-free
system. These results suggest that THC is the bona fide agent that exerts anti-cancer
bioactivity in cancer cells. The effects of these ILG derivatives or metabolites on the NLRP3
inflammasome have not been explored.
3.3. Silibinin
Silibinin (SB), also called Silybin, is a natural polyphenolic flavonoid (Figure 2 and
Table 1) from milk thistle (Silybum marianum), which has been used as an anti-inflammatory
and hepatoprotective herb [101]. Incubation of SB with differentiated THP-1 cells (a human
monocytic leukemia cell line) for two hours decreased caspase-1 autocleavage when the
NLRP3 inflammasome was activated using LPS and ATP [85]. SB had no impact on the
protein levels of NLRP3, ASC, and caspase-1 but resulted in decreased ROS production and
inflammasome complex formation. Incubation of SB with RAW264.7 cells for three hours
inhibited NF-κB signaling. The anti-NLRP3 inflammasome and anti-NF-κB properties
of SB may confer its protective effects on LPS-induced acute lung injury in mice [85]. In
another study, SB significantly reduced IL-1β release in THP-1 cells when the NLRP3
inflammasome was activated using LPS and MSU [86].
When mice were fed with a HFD to induce liver steatosis, the protein levels of NLRP3
and cleaved caspase-1 in the liver were increased but were largely blocked by the oral
administration of SB [87]. In vitro, SB suppressed IL-1β release from primary hepatocytes
and HepG2 cells that had been incubated with 100 µM of palmitic acid.
A number of SB derivatives have been synthesized, and many of them have demon-
strated increased anti-proliferative potencies, serum stability, and solubility [102,103]. SB
mainly underwent hydroxylation in phase I metabolism and glucuronidation in phase
II metabolism in vivo [104]. As with other natural compounds, the effects of these SB
derivatives and metabolites on the NLRP3 inflammasome have not been investigated.
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3.4. Cardamonin
Cardamonin (2′,4′-dihydroxy-6′-methoxychalcone, CDN) is the major flavonoid (Figure 2
and Table 1) extracted from the seeds of Alpinia Katsumadai, a traditional Chinese medicinal
herb of the ginger family that has been used for the treatment of multiple inflammatory
disorders [105]. This natural compound was found to suppress caspase-1 autocleavage and
IL-1β release upon NLRP3 inflammasome activation in immortalized mouse bone marrow-
derived macrophages (BMDMs), primary BMDMs, human THP-1 cell line-differentiated
macrophages, and human PBMCs [88]. It is interesting to note that CDN was incubated
with cells for one hour after the LPS priming step but before the addition of various NLRP3
activators, suggesting that the action of CDN on NLRP3 inflammasome activity was direct
and prompt. The inhibitory effects of CDN on the NLRP3 inflammasome were specific
because it did not inhibit activation of the NLRC4 or AIM2 inflammasome. One-hour
incubation of CDN did not affect the protein levels of NLRP3, ASC, or caspase-1 but
impeded the assembly of the NLRP3 inflammasome. When CDN was intraperitoneally
injected one hour prior to LPS injection, CDN protected mice from death and significantly
reduced serum IL-1β levels. The in vivo efficacy of CDN was comparable to MCC950 [88],
which is a well-established potent chemical inhibitor of the NLRP3 inflammasome [70].
In another study [89], similar doses of CDN were incubated with THP-1 cells or
BMDMs for 21 h, followed by NLRP3 inflammasome activation. The lengthy incubation
of cells with CDN decreased the NLRP3 protein level and expression of the Il1b gene,
accompanied by decreased levels of cleaved caspase-1 and mature IL-1β. Further in-
vestigation indicated that the aryl hydrocarbon receptor (AhR) and its downstream axis
Nrf2/NADPH:quinon acceptor oxidoreuctase 1 (NQO1) mediated the inhibitory effects of
CDN on NLRP3 inflammasome activity [89], although the study did not further elucidate
whether AhR/Nrf2/NQO1 targeted the priming step or activating step during NLRP3
inflammasome activation. The same study showed that oral or rectal administration of
CDN significantly alleviated disease severity and reduced inflammation in dextran sulfate
sodium (DSS)- or 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice, sug-
gesting the promising therapeutic potential of CDN in the management of inflammatory
bowel disease.
Nineteen derivatives of CDN were synthesized, and some of them showed increased
apoptosis-inducing potencies in cancer cell lines [106]. A recent study [107] identified
40 metabolites of CDN after it was orally administered to rats. These metabolites were
mainly derived from methylation, demethylation, hydrogenation, hydroxylation, dehy-
droxylation, glucuronidation, and sulfation of CDN in vivo. It would be important to
determine the effects of CDN derivatives or metabolites on the NLRP3 inflammasome in
future studies.
3.5. Caffeic Acid Phenethyl Ester
Caffeic Acid Phenethyl Ester (CAPE), a natural polyphenolic compound (Figure 2
and Table 1) in honeybee propolis, has been reported to possess antioxidant and anti-
inflammatory properties [108]. Remarkably, CAPE suppressed caspase-1 autocleavage,
IL-1β release, and ASC oligomerization when LPS-primed BMDMs were treated with MSU
to activate the NLRP3 inflammasome [90]. In MSU-induced gouty arthritis in mice, orally
administered CAPE significantly attenuated foot swelling and neutrophil infiltration in foot
tissues, accompanied by decreased release of IL-1β and IL-18 and reduced levels of cleaved
caspase-1 in foot tissues. Further mechanistic studies using reconstitution experiments,
pull down assay, and surface plasmon resonance (SPR) analysis showed that CAPE directly
bound to ASC. CAPE specifically bound to PYD of ASC, but not to PYD of NLRP3 or
CARD of ASC. Molecular modeling analysis suggested that CAPE seemed to interact with
Glu13 and Lys24 of ASC through hydrogen bonds and with Lys21 and Leu45 through
lipophilic interactions. The association of CAPE with ASC prevented the interaction of
ASC and NLRP3 in BMDMs upon inflammasome activation. Because CAPE targeted ASC,
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the AIM2 inflammasome, which is composed of the sensor AIM2, the adaptor ASC, and
the effector caspase-1, was unsurprisingly inhibited by CAPE treatment [90].
A recent study [91] showed that CAPE suppressed caspase-1 autocleavage, IL-1β
release, and inflammasome formation in both THP-1 cells and BMDMs when the NLRP3
inflammasome was activated using LPS and ATP. The level of NLRP3 protein was decreased
in a dose-dependent manner by CAPE treatment. Interestingly, CAPE did not affect the
mRNA level of the Nlrp3 gene. Instead, during NLRP3 inflammasome activation, CAPE
suppressed deubiquitination of the NLRP3 protein, which is a prerequisite for the assembly
of the NLRP3 inflammasome complex [5]. CAPE was found to promote interaction of
NLRP3 with the ubiquitin-conjugating enzyme Cullin1 but to decrease interaction of
NLRP3 with the deubiquitinating enzyme COP9 signalosome subunit 5 (CSN5). This
study suggests another mechanism by which CAPE suppresses activation of the NLRP3
inflammasome. CAPE was also shown to suppress NLRP3 inflammasome activity in
human aortic valve interstitial cells (AVICs) cultured in osteogenic induction medium [92].
Over 100 derivatives of CAPE were synthesized and most of them were tested for
their anti-cancer properties [109]. Recently, 48 CAPE derivatives were designed, synthe-
sized, and tested for their anti-inflammatory properties [110]. Although CAPE mildly
inhibited secretion of tumor necrosis factor alpha (TNFα) in LPS-treated mouse peritoneal
macrophages, in the initial screen, one of its derivatives, 10 s, potently inhibited the level
of TNFα in the medium. This 10s derivative was found to bind to myeloid differentiation
protein 2 (MD2) with high affinity through two key hydrogen bonds and hydrophobic
interactions. The association of 10s and MD2 blocked the interaction of LPS and MD2
and thus blunted activation of the NF-κB pathway. Therefore, in the context of NLRP3
inflammasome activation, 10s should strongly inhibit the priming step. It would be
very interesting to assess whether 10s retains the ability to bind to ASC and/or mediate
NLRP3 deubiquitination.
When CAPE was orally given to rats, the level of caffeic acid was remarkably enhanced
in urine collected within 24 h, along with moderate increase in caffeic acid phenethyl ester,
caffeic acid ethyl ester, and caffeic acid 2-(2-ethoxyethoxy)ethyl ester [111]. Future studies
are needed to investigate anti-NLRP3 inflammasome functions of these CAPE metabolites.
3.6. Ginsenosides
Ginsenosides are steroid glycosides and triterpene saponins (Figure 2 and Table 2)
that are specifically enriched in the ginseng, the root of plants in the genus Panax. Their
herb medicines have been used in Asia for thousands of years to improve stamina and
treat a variety of diseases, such as gastric ulcer, diabetes, and cancer [112]. More than
thirty ginsenosides have been identified, among which Rb1, compound K (CK), Rg3,
and 20S-protopanaxatriol (PPT) have been indicated in inhibiting NLRP3 inflammasome
activity [113].
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Rb1 is the most abundant ginsenoside in Korean ginseng (Panax ginseng), and CK is a
metabolite of Rb1 generated through hydrolysis by intestinal bacteria [119]. Chen et al. [114]
observed when eWAT of mice were cultured ex vivo with high glucose (33 mM) for
24 h, the level of NLRP3 protein and cleaved caspase-1 in the eWAT tissue and IL-1β
release in the medium were increased, but all were blunted by pretreatment with Rb1
or CK. In diabetes spontaneous mutation (Leprdb) mice (often called db/db mice), oral
administration of CK improved glucose tolerance, insulin sensitivity, cognitive function,
and memory [115]. Remarkably, the levels of mature IL-1β, NLRP3, cleaved caspase-1,
and ASC were decreased in the hippocampus of db/db mice treated with CK. Although
these animal studies pointed to the possible regulatory effects of Rb1 and CK on the
NLRP3 inflammasome, the experimental design was not able to determine whether the
decreased IL-1β release and cleaved caspase-1 in the tissues were caused by decreased
levels of the NLRP3 inflammasome subunits or due to diminished activation of the NLRP3
inflammasome. The direct effects of Rb1 or CK on NLRP3 inflammasome activation need
to be further investigated.
In a recent study [116], ginsenoside Rg3 was shown to specifically inhibit activation of
the NLRP3 inflammasome, but not the NLRC4 or AIM2 inflammasome. In LPS-primed
THP-1 cells, Rg3 reduced caspase-1 autocleavage and the secretion of IL-1β and IL18, but
it had no impact on the release of IL-6 or TNFα when the NLRP3 inflammasome was
stimulated by nigericin, ATP, or alum. Rg3 treatment did not affect upstream events of
NLRP3 inflammasome activation, such as mitochondrial ROS production or potassium
efflux. Instead, Rg3 abrogated the interaction of NEK7 and NLRP3 and therefore disrupted
NLRP3 inflammasome assembly. In LPS-induced endotoxic shock in mice, pretreatment
with Rg3 via intraperitoneal injection suppressed the levels of IL-1β in both the peritoneal
cavity and circulation and improved the survival of mice [116]. Rg3 was metabolized
into six metabolites after its oral administration in rats [120]. Therefore, it is important to
determine whether Rg3 could reach innate immune cells in vivo and/or whether any Rg3
metabolites retain inhibitory effects on the NLRP3 inflammasome.
Ginsenoside PPT is one of the terminal metabolites commonly detected in human
circulation after ingestion of ginseng [121]. Jiang et al. reported that PPT suppressed activa-
tion of the NLRP3 inflammasome, but not AIM2 or NLRC4 inflammasome, in LPS-primed
peritoneal macrophages [117]. PPT blocked ASC oligomerization and subsequent caspase-1
autocleavage and IL-1β release upon NLRP3 inflammasome activation by nigericin, ATP,
or silica, but it had no impact on the protein levels of NLRP3, ASC, or caspase-1. In
LPS-induced endotoxic shock in mice, PPT decreased serum IL-1β levels. In the mouse
model of MSU-induced acute peritonitis, PPT attenuated the level of IL-1β and neutrophil
infiltration in peritoneal lavage fluids [117]. In another recent study, PPT was shown to
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ameliorate thioacetamide-induced hepatic fibrosis and decrease protein levels of NLRP3,
cleaved caspaspe-1, and mature IL-1β in fibrotic livers [118].
A number of ginsenoside derivatives have been reported [122,123] and their functional
significance in inhibition of the NLRP3 inflammasome needs further study.
4. Conclusions and Perspectives
Tozser et al. in 2016 [11] summarized nine natural compounds with anti-NLRP3
inflammasome function. Most of these natural compounds were included in a more recent
review by Jahan et al. in 2017 [10], which overviewed 34 natural compounds possessing
inhibitory actions on the NLRP3 inflammasome. In the last three years, five more new
natural compounds have been identified with anti-NLRP3 inflammasome properties; these
are summarized in this review. Although ILG was included in Jahan’s review, only one
report was available at that time. Therefore, we added ILG to the list of most recently
identified natural compounds and included an overview of ILG’s actions based on four
more recent research articles.
The study of natural compounds with anti-NLRP3 inflammasome function is still
at an early stage. Many outstanding questions remain unanswered in this new field.
Although some elegant studies have shown that oridonin or CAPE inhibits activation of the
NLRP3 inflammasome through unique mechanisms or by targeting multiple targets, more
investigation is warranted to elucidate the detailed molecular mechanisms that enable each
natural compound to inhibit the NLRP3 inflammasome. It also would be important to
study the structural basis of anti-inflammasome properties of these natural compounds and
their derivatives, since such studies will facilitate modification and optimization during
drug development. Future studies on the bioavailability, efficacy, and safety of these
natural compounds in vivo are needed, as such information is critical to determine their
suitability for treatment of specific diseases. In addition, because natural compounds
could be converted into a variety of metabolites after oral administration, it would be
critical to assess what types of metabolites reach innate immune cells and whether these
metabolites retain anti-NLRP3 inflammasome activities. An ultimate question in the
field of anti-NLRP3 inflammasome natural compounds is how to develop efficient and
rapid strategies to fractionate and separate the crude natural extracts and identify new
active natural components. The whole natural compound field is facing the same challenge,
requiring multidisciplinary efforts and expertise from chemistry, molecular and cell biology,
physiology, and pharmacology.
Successful development of a drug from bench to bedside requires tremendous fi-
nancial and time investment. Generally, it takes 10–15 years and USD 500 million–USD
2 billion to develop a single drug [124,125]. Promising drug leads undergo comprehensive
examination in preclinical studies of absorption, distribution, metabolism, and excretion
(ADME), efficacy, and toxicity, followed by modification and production optimization.
Afterward, the candidates selected from preclinical studies enter the clinical trials (typically
four phases) and are evaluated for their efficacy and safety in humans. Unfortunately,
the whole process is associated with high failure frequency often due to low efficacy in
humans [126]. For example, only 5% of oncology drugs entering Phase I clinical trials are
eventually approved by the US Food and Drug Administration (FDA) [127]. Compared to
synthetic chemicals, development of natural product-sourced drugs is more time consum-
ing and associated with higher cost, due to the extra efforts needed to identify the active
components in crude extracts and to modify (often extensively) the base molecules [72].
Therefore, there is a long way to go for natural products with anti-NLRP3 inflammasome
functions to be eventually developed into drugs.
When these natural compound-based drugs become available in clinic, their cost-
effectiveness would facilitate their routine use in treatment of chronic diseases such as
autoinflammatory disease CAPS. Very often, such natural compound-derived drugs can be
taken orally and thus avoid the side effects associated with frequent injection. However, one
complication of using NLRP3 inflammasome inhibitors in treating chronic inflammation
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lies in potential inherent adverse effects. Proper activation of the NLRP3 inflammasome is
part of the host’s protective inflammatory response against pathogens and other detrimen-
tal insults [2,128]. Long-term and continuous inhibition of the NLRP3 inflammasome may
compromise the host’s normal immune defense function and therefore increase the risk of
infections. One possible solution is to use a highly specific drug against the NLRP3 inflam-
masome and thus leave other innate immune responses intact. Intermittent administration
of these inhibitor-based drugs could be another option. Furthermore, selection of different
natural compounds with different molecular targets or tissue distribution could help to
reach maximal clinical outcomes while limiting undesirable side effects.
Finally, it is worthwhile mentioning that many natural compounds could function
through highly selective and totally unexpected new pathways. Therefore, investigating
the molecular mechanisms underlying their anti-NLRP3 inflammasome functions could
possibly reveal new insights and pathways of NLRP3 inflammasome activation, thus con-
tributing to a better understanding of the complex mechanisms of NLRP3 inflammasome
activation.
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